Publications by authors named "Jakob Michael Riedl"
Early kinetics of C reactive protein for cancer-agnostic prediction of therapy response and mortality in patients treated with immune checkpoint inhibitors: a multicenter cohort study.
J Immunother Cancer
December 2023
Article Synopsis
- Early C-reactive protein (CRP) kinetics may serve as a predictive biomarker for the effectiveness of immune checkpoint inhibitor (ICI) therapy across various cancer types, aiming to enhance treatment outcomes.
- A study analyzed two patient cohorts receiving palliative ICI treatment, classifying CRP kinetics into four patterns and examining their association with objective response rate (ORR), progression-free survival (PFS), and overall survival (OS).
- Results showed that patients with normal CRP levels had significantly better ORR, PFS, and OS compared to those with abnormal CRP kinetics, validating CRP kinetics as a reliable indicator of treatment efficacy regardless of cancer type.
Background/aim: The Aspartate aminotransaminase/Alanine aminotransaminase ratio (AST/ALT ratio) has been identified as a prognostic marker for several malignancies. In this study, we evaluated the prognostic value of the AST/ALT ratio in a large cohort of non-metastatic colorectal cancer patients (CRC).
Patients And Methods: A total of 536 patients with stage II and III CRC, as well as available AST/ALT ratio were included in this single-center retrospective analysis.
Background: The advanced lung cancer inflammation index (ALI) was first introduced for prognosis prediction in lung cancer patients and since then evaluated in several other malignancies. However, in pancreatic cancer (PC) the ALI and its prognostic utility were only investigated in a comparably small and specific cohort of locally advanced PC patients treated with chemoradiotherapy.
Methods: In our single-center cohort study, we included 429 patients with histologically verified PC who were treated between 2003 and 2015 at our academic institution.
Article Synopsis
- - The study investigates the role of butyrylcholinesterase (BChE) activity in blood as a potential indicator of liver function and its association with pancreatic cancer (PC) outcomes.
- - Analyzing data from 574 PC patients, researchers found that lower levels of BChE were linked to poorer cancer-specific survival rates, highlighting its importance in prognosis.
- - The results suggest that BChE levels could be used to categorize PC patients into different risk groups based on their predicted survival times.
Background: The pretreatment De Ritis ratio [aspartate transaminase (AST)/alanine transaminase (ALT)] has been shown to be an adverse prognostic marker in various cancer entities. However, its relevance to advanced pancreatic ductal adenocarcinoma (PDAC) has not yet been studied. In the present study we investigated the AST/ALT ratio as a possible predictor of treatment response and disease outcome in patients with advanced PDAC treated with first-line gemcitabine/nab-paclitaxel.
View Article and Find Full Text PDFIntroduction: Inflammatory biomarkers are useful prognostic tools in cancer patients. However, the prognostic and predictive value of inflammatory biomarkers beyond the 1-line setting in metastatic colorectal cancer (mCRC) is unclear.
Results: In multivariate analysis 1 standard deviation increase in neutrophil-lymphocyte-ratio (NLR) was associated with an 8.
Background: Venous thromoboembolism (VTE) is a frequent and burdensome complication of metastatic colorectal cancer (CRC). However, the epidemiology of VTE in patients with localized CRC after surgery in curative intent is incompletely understood. In this single-center observational cohort study, we investigate patterns of VTE risk in localized CRC, and define its relationship with baseline risk factors, adjuvant chemotherapy and CRC recurrence.
View Article and Find Full Text PDF